Equities research analysts at Wedbush issued their Q1 2026 earnings estimates for shares of Black Diamond Therapeutics in a ...
TScan Therapeutics (NASDAQ:TCRX – Free Report) had its price objective trimmed by Barclays from $14.00 to $3.00 in a report ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback